Table 3 Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different SLCO1B1 genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups AI, AII, AIII)
Subgroup | SLCO1В1 genotypes | Total cholesterol (mmol/L) | LDL cholesterol (mmol/L | ||||
|---|---|---|---|---|---|---|---|
Baseline | 4-month follow-up | Change | Baseline | 4-month follow-up | Change | ||
Subgroup AI (Rosuvastatin) | 521СС (n = 6) | 7.15 ± 0.14 | 5.75 ± 0.16* | −19.6% | 4.95 ± 0.15 | 3.37 ± 0.14** | −31.9% |
521ТТ (n = 15) | 7.10 ± 0.14 | 4.61 ± 0.15*** | −35.1% | 4.96 ± 0.17 | 2.93 ± 0.15*** | −41.0% | |
521СТ (n = 9) | 7.17 ± 0.15 | 4.86 ± 0.17*** | −32.2% | 4.99 ± 0.18 | 3.10 ± 0.19*** | −37.9% | |
Mean (n = 30) | 7.13 ± 0.11 | 4.94 ± 0.14*** | −30.7% | 4.97 ± 0.17 | 3.08 ± 0.16*** | −38.0% | |
Subgroup AII (Atorvastatin) | 521СС (n = 6) | 7.17 ± 0.17 | 5.74 ± 0.21* | −19.7% | 5.12 ± 0.27 | 3.61 ± 0.28** | −29.5% |
521ТТ (n = 16) | 7.19 ± 0.14 | 5.21 ± 0.19*** | −27.3% | 5.09 ± 0.19 | 3.10 ± 0.22*** | −39.1% | |
521СТ (n = 8) | 7.19 ± 0.15 | 5.24 ± 0.18*** | −27.1% | 4.99 ± 0.20 | 3.18 ± 0.27*** | −36.3% | |
Mean (n = 30) | 7.15 ± 0.18 | 5.29 ± 0.25*** | −26.2% | 5.06 ± 0.26 | 3.19 ± 0.25*** | −36.9% | |
Subgroup AIII (Simvastatin) | 521СС (n = 8) | 7.16 ± 0.21 | 5.78 ± 0.22* | −19.3% | 5.13 ± 0.19 | 3.67 ± 0.17** | −28.5% |
521ТТ (n = 12) | 7.12 ± 0.19 | 4.83 ± 0.18*** | −32.2% | 5.14 ± 0.17 | 3.08 ± 0.18*** | −40.1% | |
521СТ (n = 10) | 7.11 ± 0.20 | 4.79 ± 0.21*** | −32.6% | 5.09 ± 0.21 | 3.07 ± 0.16*** | −39.7% | |
Mean (n = 30) | 7.13 ± 0.18 | 5.07 ± 0.23*** | −28.9% | 5.12 ± 0.18 | 3.23 ± 0.23*** | −36.9% | |